About aTTP/iTTP CABLIVI (caplacizumab-yhdp)

What is CABLIVI (caplacizumab-yhdp)?

Real Stories With CABLIVI (caplacizumab-yhdp)

Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies - ScienceDirect

Caplacizumab: Uses, Interactions, Mechanism of Action

Ranga Welaratne on LinkedIn: Sanofi Promise Warranty Program for Cablivi® ( caplacizumab-yhdp) Seeks to…

Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the caplacizumab era - ScienceDirect

Sanofi Cablivi is approved by Canada for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)! - Knowledge - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd

These highlights do not include all the information needed to use CABLIVI® safely and effectively. See full prescribing information for CABLIVI. CABLIVI (caplacizumab-yhdp) for injection, for intravenous or subcutaneous use Initial U.S.

CABLIVI (caplacizumab-yhdp) Resources for HCPs and Patients

Caplacizumab - wikidoc